The Alliance for Pulmonary Hypertension’s 2025 Webinar Series: Uniting the Global Community – With Gratitude to Our Speakers and Participants

The Alliance for Pulmonary Hypertension’s quarterly webinars aim to keep the community informed and connected by examining recent advancements, emerging research, and new initiatives in pulmonary hypertension. Through a blend of expert (scientific and patient) presentations and open dialogue, these sessions encourage active participation and create space for diverse perspectives from patients, caregivers, and healthcare […]

The Alliance for Pulmonary Hypertension’s 2025 Webinar Series: Uniting the Global Community – With Gratitude to Our Speakers and Participants Read Post »

Celebrating the Alliance for Pulmonary Hypertension’s first 18 “PEP Talks” since the launch of the program in May 2025, and looking forward to many more in 2026!

The Alliance for Pulmonary Hypertension introduced its 2025 “Patients Empowering Patients” (PEP) program, designed to harness the power of peer-to-peer support, on May 5, 2025, World Pulmonary Hypertension Day. The name “PEP Talks” is a playful nod to the acronym of the “PEP” program, and it embodies the encouraging and motivational spirit of traditional pep

Celebrating the Alliance for Pulmonary Hypertension’s first 18 “PEP Talks” since the launch of the program in May 2025, and looking forward to many more in 2026! Read Post »

The Discovery of Inhaled Prostanoids for Pulmonary Hypertension, Prof. Werner Seeger, Pulmonary Circulation, December 18, 2025

A very interesting article by Prof. Werner Seeger recounts the discovery and development of inhaled prostanoids for pulmonary hypertension at the Giessen Pulmonary Hypertension center (Germany) in the late 1980s-1990s (§). Initially researching acute lung injury/Acute Respiratory Distress Syndrome (ARDS), researchers at Giessen observed that while intravenous vasodilators worsened ventilation/perfusion mismatch, aerosolized prostacyclin (PGI2) reduced

The Discovery of Inhaled Prostanoids for Pulmonary Hypertension, Prof. Werner Seeger, Pulmonary Circulation, December 18, 2025 Read Post »

Use of Sotatercept to Facilitate Transition From Intravenous to Oral Prostacyclin Therapy for Pulmonary Arterial Hypertension, Clinical Respiratory Journal, December 19, 2025

Parenteral prostacyclin therapy remains the cornerstone for high-risk pulmonary arterial hypertension (PAH) patients but is limited by complications and reduced quality of life. A case series of eight high-risk patients demonstrated that adding sotatercept successfully enabled transition from intravenous to oral prostacyclin therapy. All patients received background dual therapy with endothelin receptor antagonists and phosphodiesterase-5

Use of Sotatercept to Facilitate Transition From Intravenous to Oral Prostacyclin Therapy for Pulmonary Arterial Hypertension, Clinical Respiratory Journal, December 19, 2025 Read Post »

ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of reveal risk score, Vascular Pharmacology, November 29, 2025

The ASPYRE-1 study presents the baseline characteristics of patients enrolled in the national prospective registry created through the Italian Network on Pulmonary Arterial Hypertension (IPHNET). The registry was established in 2014 with the aim of better understanding the contemporary profile of Italian pulmonary arterial hypertension patients and to support future analyses on risk stratification and

ASPYRE-1 study: An Italian multicenter prospective study on pulmonary hypertension modality of death and validation of reveal risk score, Vascular Pharmacology, November 29, 2025 Read Post »

Patient-reported Functional Class (FC) may better reflect pulmonary hypertension burden than physician-assigned Functional Class, CHEST, November 27, 2025

A new study published recently on CHEST evaluated whether the Pulmonary Hypertension Functional Class Self-Report (PH-FC-SR)—a patient-reported version of the World Health Organisation (WHO) Functional Class—captures functional status in a way that reflects patients’ real experiences. Study Overview Eighty-nine adults with pulmonary hypertension (Groups 1–5) from the Cleveland Clinic and Mayo Clinic completed an online

Patient-reported Functional Class (FC) may better reflect pulmonary hypertension burden than physician-assigned Functional Class, CHEST, November 27, 2025 Read Post »

Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases, JA Clinical Reports, November 29, 2025

This is a small study but it addresses a very important but often overlooked issue, that of injection site pain for pulmonary arterial hypertension patients being treated with sub-cutaneous treprostinil, which can significantly affect quality of life. The researchers found that topical 10% lidocaine gel provided rapid and effective relief of injection site pain, facilitating

Efficacy of 10% lidocaine gel for injection site pain associated with treprostinil in the treatment of pulmonary hypertension: a report of four cases, JA Clinical Reports, November 29, 2025 Read Post »

A comprehensive review of drugs and toxins associated with pulmonary arterial hypertension offers clinicians updated guidance, European Respiratory Journal Open Research, November 2025 

A review recently published in the European Respiratory Journal Open Research provides the latest evidence on drug- and toxin-associated pulmonary arterial hypertension, offering clinicians updated guidance on recognition, diagnosis, and management of this pulmonary arterial hypertension subtype (see below for the most recent pulmonary arterial hypertension classification, at 1.3) The first World Health Organization (WHO)

A comprehensive review of drugs and toxins associated with pulmonary arterial hypertension offers clinicians updated guidance, European Respiratory Journal Open Research, November 2025  Read Post »

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension, Pulmonary Circulation, November 20, 2025

Pulmonary arterial hypertension (PAH) is a progressive, life-threatening disease where early detection is strongly encouraged to prevent irreversible vascular and cardiac damage. However, a fundamental paradox exists: while clinicians are urged to diagnose pulmonary arterial hypertension early, treatment is restricted to symptomatic patients (New York Heart Association (NYHA) functional class II or higher), leaving asymptomatic

Why Wait for Sick People to Get Sicker? The Paradox of the Treatment of Patients With Pulmonary Arterial Hypertension, Pulmonary Circulation, November 20, 2025 Read Post »

GDF15 is a promising biomarker for distinguishing pulmonary veno-occlusive disease (PVOD) and pulmonary arterial hypertension (PAH), Journal of Clinical Investigation, November 20, 2025

Pulmonary veno-occlusive disease (PVOD) is a rare, severe World Health Organisation Group 1 pulmonary arterial hypertension (PAH) subtype with poor survival. pulmonary arterial hypertension-targeted vasodilators can cause life-threatening pulmonary edema in Pulmonary veno-occlusive disease, underscoring the need for diagnostic tools to distinguish it from other pulmonary arterial hypertension subtypes The findings of a study recently

GDF15 is a promising biomarker for distinguishing pulmonary veno-occlusive disease (PVOD) and pulmonary arterial hypertension (PAH), Journal of Clinical Investigation, November 20, 2025 Read Post »

“Heart Works” – phaware® – a New Pulmonary Hypertension App from Phaware Global Association®

“Heart Works” key features: Real-time health data tracking: including advanced quality-of-life surveys and 6-minute walk tests, allowing patients to closely monitor their progression. Access to Phaware resources: 500+ curated phaware® podcasts, webinars, and expert interviews on pulmonary hypertension. Access to international resources: Thanks to partnerships with leading organizations including Stanford Wall Center, University of Alberta,

“Heart Works” – phaware® – a New Pulmonary Hypertension App from Phaware Global Association® Read Post »

Evolving paradigms in pulmonary hypertension: Highlights of the 6th French Pulmonary Hypertension Network Meeting, Respiratory Medicine and Research, Vol 88, November 2025

The 6th “Journées du Réseau Français de l’Hypertension Pulmonaire” (JRF-HTP), held in October 2024, provided a review of the evolving landscape in pulmonary hypertension (PH). The meeting brought together clinicians and researchers to exchange on the most recent scientific, clinical, and organizational advances in pulmonary hypertension. We are proud that a patient advocate was included as co-author,

Evolving paradigms in pulmonary hypertension: Highlights of the 6th French Pulmonary Hypertension Network Meeting, Respiratory Medicine and Research, Vol 88, November 2025 Read Post »

New edition of emPHasis, the UK Pulmonary Hypertension Association (PHA UK)’s magazine is just out

The two main highlights of this edition are the report of the UK Pulmonary Hypertension survey on what symptoms affect patients most (pages 9-12) and the association’s 25th anniversary celebrations in Birmingham (pages 16-18). For the survey there were 232 responses from patients and 35 responses from caregivers. KEY FINDINGS – THE PATIENT VIEW MOST

New edition of emPHasis, the UK Pulmonary Hypertension Association (PHA UK)’s magazine is just out Read Post »

Treatment options for children with pulmonary arterial hypertension associated with congenital heart disease (PH-CHD), Expert Review of Respiratory Medicine, October 30, 2025

Pulmonary hypertension associated with congenital heart disease (PAH-CHD) is one of the most common causes of pulmonary hypertension in children. Patients fall into different subgroups, each requiring specific treatment approaches. According to an article recently published in the Expert Review of Respiratory Medicine current management is clear for two groups: The challenge The management of

Treatment options for children with pulmonary arterial hypertension associated with congenital heart disease (PH-CHD), Expert Review of Respiratory Medicine, October 30, 2025 Read Post »

Lung Transplant Allocation System Challenges for Pulmonary Arterial Hypertension (PAH) Patients, Letter to the Editor, Transplant International, October 28, 2025

Pulmonary arterial hypertension patients face unique challenges in lung transplantation. Unlike patients with other lung diseases, they often have relatively normal lung function tests but are in critical condition due to heart failure. This means they receive low priority scores in the standard Lung Allocation Score (LAS) system, which was designed primarily for patients with

Lung Transplant Allocation System Challenges for Pulmonary Arterial Hypertension (PAH) Patients, Letter to the Editor, Transplant International, October 28, 2025 Read Post »

Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: Treatment Patterns and Risk Trajectories, Pulmonary Circulation, November 11, 2025

Access to specialized care may differ between urban and rural patients, potentially influencing outcomes. A study conducted at the at the University of Utah Pulmonary Hypertension Center compared 263 pulmonary arterial hypertension patients from urban versus rural areas treated in the period 2020-2024. Similar at baseline: Important differences emerged: Conclusion: Despite similar care delivery and

Comparing Pulmonary Arterial Hypertension Care in Urban and Rural Settings: Treatment Patterns and Risk Trajectories, Pulmonary Circulation, November 11, 2025 Read Post »

Latest edition on the Council of Europe’s European Directorate for the Quality of Medicines and HealthCare (EDQM) Newsletter Transplant 2025 is now available

The Council of Europe’s EDQM (European Directorate for the Quality of Medicines and HealthCare) Newsletter Transplant provides regular updates on transplantation-related developments across Europe. It covers policy, regulation, quality standards, and best practices related to organ donation, allocation, and transplant safety, ensuring harmonisation across European Union member states. Additionally, the newsletter shares news on scientific

Latest edition on the Council of Europe’s European Directorate for the Quality of Medicines and HealthCare (EDQM) Newsletter Transplant 2025 is now available Read Post »

Integrating Sotatercept Into Pulmonary Arterial Hypertension (PAH) Care: Vallerie McLaughlin, MD, American Heart Association, November 9, 2025

Vallerie McLaughlin, MD, the Kim A. Eagle M.D. Endowed Professor of Cardiovascular Medicine and Professor of Internal Medicine at the University of Michigan Medical School, presented the results of a pooled analysis of the PULSAR, STELLAR, and ZENITH trials of sotatercept in pulmonary arterial hypertension at the 2025 American Heart Association Scientific Sessions, held in

Integrating Sotatercept Into Pulmonary Arterial Hypertension (PAH) Care: Vallerie McLaughlin, MD, American Heart Association, November 9, 2025 Read Post »

Preferences for pulmonary arterial hypertension (PAH) medications: insights from interviews with patients and doctors, Future Cardiology, November 4, 2025

A study titled “Single‑Tablet Combination Therapy of Macitentan/Tadalafil for Patients with Pulmonary Arterial Hypertension: Qualitative Interview Study” interviewed 26 pulmonary arterial hypertension patients and 18 doctors from the A DUE clinical trial, who tested the single-pill combination therapy (macitentan+tadalafil) versus taking multiple pills daily. Both patients and doctors agreed that taking one pill daily instead

Preferences for pulmonary arterial hypertension (PAH) medications: insights from interviews with patients and doctors, Future Cardiology, November 4, 2025 Read Post »

Study provides proof-of-concept that fully automated, algorithm-driven tacrolimus dosing can improve therapeutic drug monitoring in real-world clinical practice, Clinical Pharmacology and Therapeutics, October 11, 2025

Tacrolimus therapeutic drug monitoring is challenging due to high inter- and intra-patient variability. A prospective randomized controlled trial was conducted by researchers at the University Hospital in Leuven, Belgium, on 293 de novo kidney transplant recipients during the first 14 days post-transplant. A fully automated Model-informed precision dosing (MIPD) application (1) was integrated into the

Study provides proof-of-concept that fully automated, algorithm-driven tacrolimus dosing can improve therapeutic drug monitoring in real-world clinical practice, Clinical Pharmacology and Therapeutics, October 11, 2025 Read Post »

TRANSLATE »
Scroll to Top